Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15017 total
Dyne Therapeutics fell 13% on the week to $15.92 — yet options traders are suddenly the most bullish they've been all year. The options signal is the sharpest thing in this week's data. The put/call ratio collapsed to…
Snowflake has delivered its sharpest weekly gain in months, with the stock up nearly 12% to $169.55 after reporting Q1 results on May 20 — but the options market is sending a more cautious signal than the price action…
Rocket Companies heads into the final days of May with two things moving in the same direction: short interest keeps rising and options traders are growing more cautious — yet the borrow market remains wide open,…
Relay Therapeutics exits its Q1 earnings week with an unusual split: the Street just raised price targets across the board, yet shorts are adding and the stock is down 7% on the week. The analyst move this week is the…
STLAM arrives at its May 21 Q1 results with the stock down 15% over the past month, shorts still firmly in place, and a valuation that is testing the patience of even cautious bulls. The positioning picture has shifted…
Praxis Precision Medicine enters the final stretch before its June 10 earnings with options defensiveness at a year-long peak — even as short sellers quietly reduce their exposure. The options market is flashing its…
C3.ai approaches its June 3 earnings with short interest near a multi-month high, founder selling accelerating, and a Street that remains deeply split on whether the company's federal bookings surge can offset…
Digi Power X heads into this week carrying a striking split: the stock has more than doubled in a month while short sellers quietly rebuild positions and the borrow pool tightens — a setup worth watching closely. The…
Vertiv Holdings Co faces a sharp tension this week. Every major analyst is raising targets. Yet the stock just shed 12% in five days. That gap between Wall Street enthusiasm and price action is the story. The analyst…
Immunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the…
StepStone Group is reporting fiscal Q4 results tonight against a backdrop where the stock has already given up 6.5% on the week, making the print arguably more consequential than usual. Options traders are notably more…
BUG — the Global X Cybersecurity ETF — has delivered one of the more striking price moves in the ETF universe recently, up 25% over the past month and nearly 9% in a single week to $32.75. The tension this week is…
InMode heads into the week with one notable tension: options traders are the most defensively positioned they have been in months, even as short sellers have been steadily trimming exposure since April. The clearest…
Borr Drilling Limited walks into its Q1 2026 results — due May 21 — carrying two sharply contrasting signals: the founder has been accumulating stock at multi-month lows, while options traders have swung to one of the…
Phreesia heads into its May 27 earnings call carrying fresh analyst downgrades, an active securities class action, and a stock trading near $9 — a long way from where the Street was targeting it just two months…
PSNL is up 16.6% in a week and call buyers have flooded the options market — yet short sellers are adding, not covering, and the Street is trimming targets post-earnings. Options positioning has swung to one of its…
CrowdStrike enters its June 2 earnings cycle in an unusual spot: the stock has rallied 13% in a week to $616.88 — yet the consensus analyst target sits nearly 15% below the current price at $527. Something has to give,…
Uber Technologies heads into the back half of May with the most bearish options positioning of the past year — while the stock quietly sheds nearly 4% over the month to $74.09. The clearest signal this week is in…
Trevi Therapeutics enters the final stretch before its June 3 catalysts with a sharp 10.3% weekly decline creating a notable tension: every analyst still rates the stock a buy, yet the market has pulled it down 13% in…
ZM reports Q1 fiscal 2027 results after the close on May 21 — and the setup heading in is notably less comfortable than a month ago. The stock has given back 5.4% this week to $97.39, reversing part of its 10.6% April…
